[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 174.129.114.211. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
Health Care Reform
December 2015

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalAn Analysis of 5 Years of US Food and Drug Administration Approvals

Author Affiliations
  • 1Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 2Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland
JAMA Intern Med. 2015;175(12):1992-1994. doi:10.1001/jamainternmed.2015.5868

Most contemporary approvals of new cancer drugs are made on the basis of a surrogate end point, such as response rate or progression-free survival (PFS).1 When the approval is based on a surrogate end point, subsequent studies are advised and often obligated to clarify the drug’s effect on overall survival. One such drug is bevacizumab, which received accelerated approval on the basis of PFS for patients with metastatic breast cancer. Later findings revealed no improvement in overall survival and significant toxicity, which required a removal of marketing authorization.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×